GSK 3277511A

Drug Profile

GSK 3277511A

Alternative Names: GSK3277511; GSK3277511A; NTHi/Mcat-vaccine

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Vaccines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Phase I Respiratory tract disorders

Most Recent Events

  • 27 Nov 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease (Prevention) in Germany, France, Spain, United Kingdom (IM) (EudraCT2017-000880-34) (NCT03281876)
  • 16 Sep 2017 GlaxoSmithKline plans a phase II trial for Respiratory tract disorders (NCT03281876)
  • 30 Jun 2017 GlaxoSmithKline initiates enrolment in a phase I trial in Healthy volunteers in Belgium before June 2017(NCT03201211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top